NR4A1 and breast carcinoma: In contrast, our main randomized clinical trial (RCT) demonstrated in 153 postmenopausal women with hormone receptor-positive early-stage breast cancer within two years post-primary breast cancer therapy that exercise improved measures of processing speed relative to the control group (Bender et al., 2024).